Disease
7 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 4, 2026 · JOURNAL ARTICLE
International Journal of Health and Pharmaceutical Research
A narrative review synthesizing epidemiology, risk factors, and public health implications of youth-onset T2DM, with recommendations for multi-level intervention rather than testing a specific clinical hypothesis.
SEP 4, 2026 · JOURNAL ARTICLE
Biomedical Engineering Letters
A narrative review mapping electrical strategies and physiological mechanisms of vagus nerve stimulation for obesity, raising questions about optimal targeting rather than reporting primary efficacy data.
SEP 3, 2026 · JOURNAL ARTICLE
Diabetes Care
Expert consensus perspective on SGLT inhibitor use in type 1 diabetes, outlining mechanisms, trial design recommendations, and safety requirements rather than presenting new clinical trial data.
SEP 3, 2026 · JOURNAL ARTICLE
Current Issues in Sport Science
This is a keynote presentation summarizing the current state and potential of digital solutions in exercise therapy for diabetes and obesity, based on existing evidence and expert consensus rather than reporting original research findings.
SEP 3, 2026 · REVIEW
Biomedicines
A narrative review synthesizing observational evidence that raises mechanistic questions about diabetes technology and liver disease, but reports no direct clinical outcomes and explicitly acknowledges evidence remains limited, indirect, and inconsistent.
AUG 13, 2026 · JOURNAL ARTICLE
The Russian Archives of Internal Medicine
A narrative review synthesizing evidence on a proposed reclassification framework for diabetes; provides conceptual guidance on personalized treatment approaches but does not present original efficacy data or comparative clinical outcomes.
AUG 7, 2026 · REVIEW
The Indonesian Journal of General Medicine
Systematic review of 32 RCTs with 29,958 participants demonstrating consistent, clinically significant HbA1c reduction (−0.5% to −1.75%, all p<0.001) and weight loss across diverse comparators, with low risk of bias in 23 studies and GRADE-assessed certainty.